The team lead by Sílvia Vilares Conde, from CEDOC-NOVA Medical School, in collaboration with the pharmaceutical company Galvani Bioelectronics, demonstrated through findings in rats that is possible to restore insulin sensitivity and glucose homeostasis, by modulating electrically the carotid sinus nerve, the sensitive nerve that connects the carotid body with the brain.
The study is published in Diabetologia, the journal of the European Association for the Study of Diabetes [EASD].
In 2013, Silvia Vilares Conde and her research group described that the carotid body, a paired organ that is located in the bifurcation of the common carotid artery and that is classically defined as an oxygen sensor, regulates peripheral insulin sensitivity and that its dysfunction is involved in the development of metabolic diseases.
This first study and others afterwards performed by her group in diabetic rats showed that the bilateral resection of the carotid sinus nerve, and therefore the abolishment of the connection between the carotid body and the brain, restore insulin sensitivity and glucose tolerance. Although efficient this surgical irreversible approach has disadvantages, since the carotid body possess other physiological functions as the response to the lack of oxygen (hypoxia) or the adaptation to exercise. Silvia Conde’s team also described that the carotid body is over-activated in animal models of type 2 diabetes, suggesting that decreasing the activity of the organ could be a good therapeutic strategy.
From the partnership with Galvani Bioelectronics (former Glaxo Smith Kline Bioelectronics), the opportunity to electrically modulate the carotid sinus nerve come up. In fact, this work demonstrated that is possible to maintain glucose homeostasis in animals in which electrodes have been implanted in the carotid sinus nerve and submitted to electrical modulation, without significant adverse effects. It has also been demonstrated that the electrical modulation is reversible. Silvia Conde notes that “this work opens the door to the development of a new therapeutic for type 2 diabetes that will provide a long-term management of the disease with negligible adverse effects and interference with daily activities”.
Type 2 diabetes is characterized by insulin resistance and by increased hepatic glucose production that culminates in hyperglycemia. Although a lot of efforts have been performed until the date none therapeutic induce long-term glycaemia control, being expected for the next decades a huge increase in the prevalence of the disease. Thus, this work gives hope to patients with metabolic diseases, as it brings a new approach for the management of type 2 diabetes.
The Latest on: Type 2 diabetes
- A diabetes drug has been recalled because it contains a cancer-causing agenton October 9, 2020 at 6:22 am
Indian pharmaceutical company Marksans Pharma Limited is recalling Metformin Hydrochloride Extended-Release Tablets because its levels of NDMA, a "probable human carcinogen," were higher than the ...
- Emerging Data on Diabetes and COVID-19 Reassuringon October 9, 2020 at 4:04 am
Two new studies add to evidence that most people with type 1 diabetes are not at excessively higher risk for COVID-19 mortality than the general population.
- Metformin Recall 2020: More Diabetes Medication Recalled Over Cancer Concernson October 8, 2020 at 10:48 am
Marksans Pharma has expanded its initial recall to include another 76 lots of metformin tablets in 500 and 750 mg dosages. Here's what you need to know.
- Type 2 Diabetes Drug Manufacturer Recalls 76 More Lots For Cancer Concernson October 7, 2020 at 10:39 pm
Nitrosodimethylamine in higher levels that is more than the daily recommended amount. However, it might be safer to keep taking them than to quit cold turkey ...
- Breaking your family ties to Type 2 diabeteson October 7, 2020 at 1:41 pm
Everyone in my family has Type 2 diabetes. I’m 26 and don’t want to get it. What can help me beat this family curse? Jeannie G., Dayton, Ohio A: Type 2 diabetes runs in families and there’s often a ...
- Study sheds light on molecular and cellular mechanisms that cause type 2 diabeteson October 6, 2020 at 6:08 am
Claude Knauf (INSERM) and Patrice Cani (UCLouvain) have been collaborating on molecular and cellular mechanisms in order to understand the causes of the development of type 2 diabetes and above all to ...
- Study: Improving blood sugar in Type 2 diabetes improves cognitive scoreson October 5, 2020 at 11:05 am
Controlling blood sugar levels helped people with type 2 diabetes who were overweight improve cognitive scores, but losing weight, exercise had mixed results, a new study shows.
- Why Early Bedtime May Be Best for People With Type 2 Diabeteson September 30, 2020 at 11:53 am
A study of people with type 2 diabetes found that night owls -- people who go to bed late and get up late -- tend to get little exercise, putting their health at greater risk. Understanding how sleep ...
- Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumoniaon September 29, 2020 at 11:25 am
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy. Patients given ...
- Higher 'Time in Range' May Benefit Type 2 Diabetes Patientson September 29, 2020 at 7:55 am
Patients who stayed in a target blood glucose range had lower rates of major adverse coronary events, severe hypoglycemic episodes, and microvascular events in a post hoc analysis of DEVOTE.
via Google News and Bing News